Trial Profile
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Nomacopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Akari Therapeutics
- 31 May 2018 Status changed from active, no longer recruiting to completed.
- 13 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.